Bluejay - רווח נקי למניה בארבעת הרבעונים האחרונים BJDX

In the short term, Bluejay Diagnostics (BJDX) faces pressure from global laboratories and low-cost Asian counterparts, yet its long-term potential relies on the implementation of the Symphony system and FDA approval. Growing clinic demand for rapid sepsis tests supports the momentum, while the 12-month YoY EPS growth rates visualize the current impulse. The value of 94.30 represents the latest reading for this indicator.

This indicator measures the dynamics of net income per share over a rolling year, reflecting the efficiency of value generation for shareholders. The current value of 94.30 allows for an assessment of the business scaling pace. By analyzing the annual EPS TTM growth rate, an investor can see the impact of the Symphony platform implementation and the sale of consumables in US clinics. Stable growth of this metric confirms the successful completion of FDA certification. This indicates that Bluejay Diagnostics (BJDX) is transitioning toward sustainable operating profit.